See the latest news and media coverage for AstraZeneca. We track all announcements, press releases, and industry mentions in real time, all in one place.
Science-led biopharmaceutical company
astrazeneca.comLast updated
In short: AstraZeneca saw its stock price drop amid reports of a $400 billion merger with Bristol Myers Squibb, which were later dismissed.
The C$820 million investment supports 700+ new roles while developing innovative treatments for cancers, kidney failure, COPD, and other diseases with government partnership.
Core EPS increased 11% driven by strong execution and investment in transformative technologies.
The update will be released at 07:00 BST on 27 July 2026, with a webcast at 11:45 BST.
The Phase III SERENA-6 trial also showed a 37% reduction in risk of second progression and 51% of patients achieved total ctDNA clearance.
Daiichi Sankyo Co Ltd on Wednesday said that its breast cancer drugs, Enhertu and Datroway, which are being developed in partnership with AstraZeneca PLC, have...
UBS reiterates its buy recommendation and assesses that the roughly 15 percent drop since July is exaggerated.
AstraZeneca Plc (NYSE:AZN) reported updated clinical outcomes across its oncology portfolio, demonstrating sustained long-term survival advantages in...
AstraZeneca stock is up on September 14, 2026, after fresh Phase 3 data showed Enhertu extended progression-free survival in HER2-mutant lung cancer. At the same...
Track AstraZeneca and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to AstraZeneca and other trending companies.